Finch Therapeutics Group, Inc.
FNCH$21M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaBOSTON1 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
FNCH News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Full Spectrum Microbiota
Clostridium Difficile Infection Recurrence
CP101
Clostridium Difficile Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Full Spectrum Microbiota | Phase 2 | Clostridium Difficile Infection Recurrence | - | - |
CP101 | Phase 2 | Clostridium Difficile Infection | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply